158 related articles for article (PubMed ID: 12723772)
1. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
Wade WE; Spruill WJ; Leslie RB
Am J Orthop (Belle Mead NJ); 2003 Apr; 32(4):201-5. PubMed ID: 12723772
[TBL] [Abstract][Full Text] [Related]
2. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
Olsen J; Gundgaard J; Borris LC
Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
[No Abstract] [Full Text] [Related]
3. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
Spruill WJ; Wade WE; Leslie RB
Blood Coagul Fibrinolysis; 2004 Oct; 15(7):539-43. PubMed ID: 15389119
[TBL] [Abstract][Full Text] [Related]
5. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR;
Lancet; 2002 May; 359(9319):1721-6. PubMed ID: 12049860
[TBL] [Abstract][Full Text] [Related]
6. Fondaparinux for post-operative venous thrombosis prophylaxis.
Garces K
Issues Emerg Health Technol; 2002 Aug; (37):1-4. PubMed ID: 12195605
[TBL] [Abstract][Full Text] [Related]
7. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Lassen MR; Bauer KA; Eriksson BI; Turpie AG;
Lancet; 2002 May; 359(9319):1715-20. PubMed ID: 12049858
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery.
Wade WE; Spruill WJ; Leslie RB
Am J Ther; 2004; 11(3):194-8. PubMed ID: 15133534
[TBL] [Abstract][Full Text] [Related]
10. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty.
Spruill WJ; Wade WE; Leslie RB
Am J Ther; 2004; 11(1):3-8. PubMed ID: 14704589
[TBL] [Abstract][Full Text] [Related]
11. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
12. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Turpie AG
Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Turpie AG; Eriksson BI; Lassen MR; Bauer KA
J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
Sullivan SD; Kwong L; Nutescu E
Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
O'Brien BJ; Anderson DR; Goeree R
CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
20. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]